Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_provenance.
- NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_assertion description "[Small molecule inhibitors targeting the kinase activity of ALK have proven to be effective therapies in certain ALK-driven malignancies and one such inhibitor, crizotinib, is now approved for the treatment of EML4-ALK-driven, non-small cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_provenance.
- NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_assertion evidence source_evidence_literature NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_provenance.
- NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_assertion SIO_000772 22932897 NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_provenance.
- NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_assertion wasDerivedFrom befree-20140225 NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_provenance.
- NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_assertion wasGeneratedBy ECO_0000203 NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_provenance.
- befree-20140225 importedOn "2014-02-25" NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_provenance.